Orchard Therapeutics PLC

Orchard Therapeutics — Technical Presentation (May 2023)

41 slides from Orchard Therapeutics's technical presentation, May 23, 2023

  1. Slide 1: ASGCT Data Review IR webcast

    ASGCT Data Review IR webcast May 23, 2023 Exhibit 99.1

  2. Slide 2: ASGCT IR Event Agenda

    ASGCT IR Event Agenda TIME AGENDA TOPIC SPEAKERS 8:00 – 8:10 a.m. Orchard’s HSC Gene Therapy Platform and ASGCT Overview Bobby Gaspar CEO 8:10 – 8:30 a.m. Clinical Data: OTL-203 (MPS-IH) + OTL-201 (MPS-IIIA) Leslie Meltzer CMO 8:30 – 8:40 a.m. Preclinical: OTL-204 (GRN-FTD) + OTL-104 (NOD2-CD) Bobby

  3. Slide 3: Forward-looking Statements

    Forward-looking Statements Certain information set forth in this presentation and in statements made orally during this presentation contain “forward-looking statements”. Except for statements of historical fact, information contained herein constitutes forward-looking statements and may include, bu

  4. Slide 4: Orchard's Vision to End the Devastation Caused by Severe and other Genetic Diseases

    HSC= hematopoietic stem cell Orchard’s Vision to End the Devastation Caused by Severe and other Genetic Diseases TIME VALUE Execute and deliver on rare disease portfolio Continue to build out capabilities in HSC gene therapy across regulatory, manufacturing, commercialization and access Expand on HS

  5. Slide 5: HSC Gene Therapy Offers a Highly Differentiated Approach

    Other Organ Systems Areas for potential future expansion Monocyte / Macrophage T cells B cells NK cells Megakaryocyte Erythrocyte Granulocyte Brain High area of focus GI Integration Self-renewal Literature references: Alessia Capotondo, Rita Milazzo, Letterio Salvatore Politi, Angelo Quattrini, Ales

  6. Slide 6: Validated Rare Disease Pipeline with Opportunities for Expansion

    Validated Rare Disease Pipeline with Opportunities for Expansion

  7. Slide 7: Significant Platform Synergies Across Neurometabolic Pipeline

    Significant Platform Synergies That Can be Leveraged Across Neurometabolic Pipeline Regulatory Manufacturing Distribution Supply Chain Treatment Sites Referral Networks MLD / Libmeldy PLATFORM SYNERGIES MPS-IH MPS-IIIA

  8. Slide 8: ASGCT Snapshot

    OTL-203 for MPS-IH: New PoC data shows extensive metabolic correction in the skeletal system, including normal growth rates, improvement in joint function and progressive acquisition of motor skills OTL-201 for MPS-IIIA: Updated data from ongoing PoC study show additional favorable neurocognitive ou

  9. Slide 9: ASGCT IR Event Agenda

    ASGCT IR Event Agenda TIME AGENDA TOPIC SPEAKERS 8:00 – 8:10 a.m. Orchard’s HSC Gene Therapy Platform and ASGCT Overview Bobby Gaspar CEO 8:10 – 8:30 a.m. Clinical Data: OTL-203 (MPS-IH) + OTL-201 (MPS-IIIA) Leslie Meltzer CMO 8:30 – 8:45 a.m. Preclinical: OTL-204 (GRN-FTD) + OTL-104 (NOD2-CD) Bobby

  10. Slide 10: New OTL-203 Data in MPS-IH

    New OTL-203 Data in MPS-IH ©rchard

  11. Slide 11: MPS-IH is a Highly Debilitating, Multisystemic Condition

    MPS-IH is a Highly Debilitating, Multisystemic Condition Impacting Cognitive and Skeletal Function Deficiency of IDUA enzyme leads to accumulation of heparan and dermatan sulfate Multisystemic neurometabolic condition affecting cognition, growth and skeletal function Current standard of care: HSCT a

  12. Slide 12: OTL-203 (MPS-IH): Interim PoC Study Results Published in NEJM

    OTL-203 (MPS-IH): Interim Proof-of-Concept (PoC) Study Results Published in NEJM SD = Standard Deviation; IQ(C) = Intelligence Quotient (Cognition); Engl J Med 2021; 385:1929-1940 DOI: 10.1056/NEJMoa2106596 Neuropsychological Tests over Time Cognitive Age-Equivalent Score (Overall)

  13. Slide 13: Early Skeletal Outcome After HSPC-GT for MPS Type I Hurler

    Early Skeletal Outcome After HSPC-GT for Mucopolysaccharidosis Type I Hurler Maria Ester Bernardo, MD, PhD "Vita-Salute San Raffaele" University Medical School San Raffaele Telethon Institute for Gene Therapy Milan, Italy [email protected] 2023 ASGCT Annual Meeting

  14. Slide 14: Early Clinical Skeletal Outcome: Auxological Parameters after GT

    Early Clinical Skeletal Outcome: Auxological Parameters after GT All GT pts. exhibit longitudinal growth within expected reference ranges according to age and gender, with a median height gain greater than the one observed in an external cohort of HSCT patients following a 3-year follow-up. [Short s

  15. Slide 15: Early Clinical Skeletal Outcome: Kyphosis After GT

    Early Clinical Skeletal Outcome: Standing & Sitting Kyphosis After GT Clinically measurable reduction in both sitting and standing kyphosis in the majority of the pts. Baseline +2 Years +3 Years Sitting Kyphosis (°) MPSIH004 +3 Years 2023 ASGCT Annual Meeting

  16. Slide 16: Early Functional Skeletal Outcome

    Early Functional Skeletal Outcome Complete and earlier normalization of joint mobility (shoulder abduction and flexion, hip and knee extension ROM) as compared with an external cohort of HSCT pts. TMQ by Peabody scale MPSIH004, Baseline MPSIH004, 36 months past GT 2023 ASGCT Annual Meeting

  17. Slide 17: Data Takeaways and Next Steps OTL-203

    Data Takeaways and Next Steps OTL-203 (MPS-IH) Moving into a Registrational Trial in 2H 2023 Randomized controlled trial vs. HSCT 40 patients 2-year primary analysis Complication free survival composite endpoint New data shows extensive metabolic correction in the skeletal system, including normal g

  18. Slide 18: New OTL-201 Data in MPS-IIIA

    New OTL-201 Data in MPS-IIIA ©rchard

  19. Slide 19: MPS-IIIA is a Progressive and Devastating Disease

    SGSH = N-Sulfoglucosamine Sulfohydrolase Shapiro EG, et al. J Pediatr 2016;170:278-87. Photos adapted from Natural History of Sanfilippo Syndrome in Spain; Orphanet Journal of Rare Diseases · December 2013 MPS-IIIA is a Progressive and Devastating Disease Sanfilippo Syndrome type A; pathogenic varia

  20. Slide 20: Heparan Sulfate Levels – Reduction in CNS and periphery

    Rapid decreases from baseline of heparan sulfate in urine and CSF were seen in all evaluated patients. Reduction in CSF HS has never been achieved with allogeneic HSCT Urine HS Levels CSF HS Levels Heparan Sulfate Levels – Reduction in CNS and periphery 2023 ASGCT Annual Meeting

  21. Slide 21: Neurocognitive Outcomes

    Neurocognitive Outcomes Patient 05-003 and 05-006 reached the ceiling of the Bayley scale (BSID-III) at 18/24 months and progressed onto the Kaufmann assessment (KABC-II) at 24/30 months Patient 05-003 is the first MPSIIIA patient with rapidly progressive phenotype at Manchester able to complete the

  22. Slide 22: Neurocognitive Outcomes

    Neurocognitive Outcomes 2023 ASGCT Annual Meeting Change in cognitive function (age equivalent scores) against natural history of MPSIIIA Change in patient behavior, patient QoL and daily living Early follow-up in trial patients Gain of skills in line with development of normal children in 4 out of

  23. Slide 23: OTL-201 POC Conclusions

    Robust, prompt, sustained, multi-lineage engraftment of genetically modified cells Supra-physiological levels of SGSH enzyme in leukocytes and CSF and rapid and significant reduction of substrate observed in all compartments 4 / 5 patients are demonstrating gain of cognitive skills in line with deve

  24. Slide 24: ASGCT IR Event Agenda

    ASGCT IR Event Agenda TIME AGENDA TOPIC SPEAKERS 8:00 – 8:10 a.m. Orchard’s HSC Gene Therapy Platform and ASGCT Overview Bobby Gaspar CEO 8:10 – 8:30 a.m. Clinical Data: OTL-203 (MPS-IH) + OTL-201 (MPS-IIIA) Leslie Meltzer CMO 8:30 – 8:40 a.m. Preclinical: OTL-204 (GRN-FTD) + OTL-104 (NOD2-CD) Bobby

  25. Slide 25: OTL-204 for GRN-FTD

    OTL-204 for GRN- FTD Section ©rchard thera peutics

  26. Slide 26: Frontotemporal Dementia (FTD) Disease Background

    www.ninds.nih.gov Frontotemporal Dementia (FTD) Disease Background Second most common dementia in people under 65 after Alzheimer’s Disease (onset at ~58) Atrophy of frontal and temporal lobes Progressive changes in behavior and personality: Early decline in social and personal interactions, depress

  27. Slide 27: GRN-FTD Represents Large and Growing Opportunity

    Sources: Knopman DS, Roberts RO. J Mol Neurosci. 2011, Onyike CU, Diehl-Schmid J. Int Rev Psychiatry. 2013 and Riedl L, et al Neuropsychiatr Dis Treat. 2014 GRN-FTD Represents Large and Growing Opportunity GRN-FTD is a growing opportunity Haploinsufficiency of progranulin (GRN) strongly associated w

  28. Slide 28: hGRN HSC-GT PoC of efficacy study

    hGRN HSC-GT PoC of efficacy study Y-Maze 3-Chamber 28 | SIN/LTR SIN/LTR hGRN_wt WPRE* PGK SIN/LTR SIN/LTR hGRN_wt WPRE* HLA VS 2023 ASGCT Annual Meeting

  29. Slide 29: Normalization of Glucosylsphingosine in Transplanted Mice

    Therapeutic Effect Evidenced by Normalization of Glucosylsphingosine in Transplanted Mice 29 | Plasma glycosphingolipid quantification by LC-MS/MS 2023 ASGCT Annual Meeting

  30. Slide 30: hGRN improves lipofuscinosis in Knockout Mice

    Hippocampus (CA3) Thalamus (VPM) Wild-Type Grn-/- Mock Grn-/- Treated hGRN improves lipofuscinosis in Knockout Mice Preliminary data Prefrontal Cortex DAPI Autofluorescence 2023 ASGCT Annual Meeting

  31. Slide 31: hGRN reduces microgliosis and Lamp-1 immunoreactivity

    Iba-1 DAPI hGRN reduces microgliosis and Lamp-1 immunoreactivity Preliminary data Thalamus Lamp-1 Thalamus Iba-1 Wild-Type Grn-/- Mock Grn-/- Treated DAPI Lamp-1 2023 ASGCT Annual Meeting

  32. Slide 32: Summary and conclusions

    Summary and conclusions Data from in vivo studies indicate effective GRN protein delivery to the CNS of knockout mice transplanted with gene-modified HSCs. A therapeutic effect in transplanted knockout mice is evidenced by: Normalization of glucosylsphingosine, a specific lipid biomarker in the plas

  33. Slide 33: OTL-104 for NOD2-Crohn's

    OTL-104 for NOD2-Crohn’s Section

  34. Slide 34: Crohn's Disease Overview

    Crohn’s Disease Overview NOD2 function: detection of bacterial peptides > 60 reported NOD2 mutations 3 SNPs exhibit strongest association NOD2 Crohn’s patients are more refractory to therapy & have more severe disease 20-40% of Crohn’s patients carry NOD2 mutations Contributing causal factors Enviro

  35. Slide 35: HSC-derived myeloid cells from NOD2-mutFS patients show impaired MDP responses

    Healthy Donors, NOD2 WT (n=9) Crohn’s Disease NOD2mutFS patients (n=5) Two-way Anova, p<0.05 (*) NOD2-mutFS cells + LV-NOD2 NOD2-mut-FS cells +/- LV-GFP 35 | CD34+ HSC derived myeloid cells from NOD2-mutFS CD patients show impaired responses to MDP 2023 ASGCT Annual Meeting

  36. Slide 36: Gene Therapy of NOD2KO mice reconstitutes NOD2 expression in gut

    Gene Therapy treatment of NOD2KO mice reconstitutes normal NOD2 expression within the gut and fully restores NOD2-dependent immune responses in vivo NOD2-LV transduced Lin- BM HSC NOD2KO GT-treated NOD2KO OTL-104 CHIM pr. LV-NOD2 Restoration of NOD2 gene expression in intestine Detection of NOD2 mRN

  37. Slide 37: Gene Therapy of NOD2KO mice restores NOD2-dependent immune responses

    Gene Therapy treatment of NOD2KO mice reconstitutes normal NOD2 expression within the gut and fully restores NOD2-dependent immune responses in vivo Functional reconstitution of NOD2-dependent (MDP-induced) immune activity in myeloid subsets MDP-induced neutrophil mobilisation Functional reconstitut

  38. Slide 38: OTL-104 Summary

    OTL-104, fully restores NOD2-dependent immune responses in macrophages derived from HSCs obtained from Crohn’s patients carrying biallelic NOD2 mutations to within the range of healthy donor cells Transplantation of OTL-104 in NOD2 knockout mice reconstitutes NOD2 expression in intestinal tissue res

  39. Slide 39: Orchard's Vision to End the Devastation Caused by Severe and other Genetic Diseases

    HSC= hematopoietic stem cell Orchard’s Vision to End the Devastation Caused by Severe and other Genetic Diseases TIME VALUE Execute and deliver on rare disease portfolio Continue to build out capabilities in HSC gene therapy across regulatory, manufacturing, commercialization and access Expand on HS

  40. Slide 40: Key Event Takeaways

    OTL-203 for MPS-IH - New PoC data shows extensive metabolic correction in the skeletal system, including normal growth rates, improvement in joint function and progressive acquisition of motor skills OTL-201 for MPS-IIIA - New data from ongoing PoC study show additional favorable neurocognitive outc

  41. Slide 41: Q&A

    Q&A Bobby Gaspar, M.D., Ph.D. Chief Executive Officer Leslie Meltzer, Ph.D. Chief Medical Officer

Orchard Therapeutics — Technical Presentation (May 2023) on 6ix